O-12 MIR-181A AS A BIOMARKER OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE
Introduction: Non-Alcoholic Fatty Liver Disease (NAFLD) covers a wide spectrum of disease, ranging from simple steatosis to cirrhosis. Liver biopsy is still the gold standard for assessing fibrosis, but there is a need to seek non-invasive biomarkers that can also be efficient in predicting fibrosis...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-09-01
|
| Series: | Annals of Hepatology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268121001988 |
| _version_ | 1818438082550038528 |
|---|---|
| author | Rodrigo Vieira Costa Lima Fernanda de Mello Malta José Tadeu Stefano João Renato Pinho Flair José Carrilho Claudia Pinto Marques Souza de Oliveira |
| author_facet | Rodrigo Vieira Costa Lima Fernanda de Mello Malta José Tadeu Stefano João Renato Pinho Flair José Carrilho Claudia Pinto Marques Souza de Oliveira |
| author_sort | Rodrigo Vieira Costa Lima |
| collection | DOAJ |
| description | Introduction: Non-Alcoholic Fatty Liver Disease (NAFLD) covers a wide spectrum of disease, ranging from simple steatosis to cirrhosis. Liver biopsy is still the gold standard for assessing fibrosis, but there is a need to seek non-invasive biomarkers that can also be efficient in predicting fibrosis. Objectives: To evaluate the role of microRNAs miR-21, miR-29a, miR-122, miR-155 and miR-181a in the phenotypic expression of NAFLD, correlating their serum levels with the different stages of the disease. Methods: Cross-sectional study carried out on 108 NAFLD patients diagnosed by liver biopsy. In the histological analysis, the degrees of fibrosis and NAFLD activity score (NAS) were obtained. The FIB-4 and NAFLD fibrosis score were calculated and compared with the degree of fibrosis by biopsy. The comparison between the distributions of microRNA values according to the presence or absence of clinically expressed fibrosis (F2-4) was performed. The serum expression of microRNAs was also compared with the NAS of the biopsy. A multivariate logistic regression analysis was performed to build a score for predicting fibrosis using FIB-4 and Ln (miR-181a) as independent variables. Results: Among the microRNAs studied, only miR-181a showed a statistical difference between patients with clinically expressed fibrosis and those without fibrosis (F0-F1) determined by liver biopsy (p = 0.017). FIB-4 revealed an AUC on the ROC curve of 0.667 to predict clinically expressed fibrosis (F2-F4). When assessed using the score in association with Ln (miR-181a), there was an improvement in the ROC curve, with AUC of 0.71. There was no correlation between the serum levels of microRNAs miR-21, miR-29a, miR-122, miR-155 and miR-181a with the degrees of inflammatory activity determined by NAS. Conclusion: miR-181a can be used as a non-invasive method of predicting fibrosis in NAFLD, and an association of biomarkers has the potential to increase the accuracy of each method alone. |
| first_indexed | 2024-12-14T17:34:55Z |
| format | Article |
| id | doaj.art-8b03a76ed12243a0a40b6b3ebf3857a3 |
| institution | Directory Open Access Journal |
| issn | 1665-2681 |
| language | English |
| last_indexed | 2024-12-14T17:34:55Z |
| publishDate | 2021-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj.art-8b03a76ed12243a0a40b6b3ebf3857a32022-12-21T22:53:01ZengElsevierAnnals of Hepatology1665-26812021-09-0124100499O-12 MIR-181A AS A BIOMARKER OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASERodrigo Vieira Costa Lima0Fernanda de Mello Malta1José Tadeu Stefano2João Renato Pinho3Flair José Carrilho4Claudia Pinto Marques Souza de Oliveira5Division of Clinical (LIM-07), Department of Gastroenterology, University of São Paulo School of MedicineDivision of Clinical (LIM-07), Department of Gastroenterology, University of São Paulo School of MedicineDivision of Clinical (LIM-07), Department of Gastroenterology, University of São Paulo School of MedicineDivision of Clinical (LIM-07), Department of Gastroenterology, University of São Paulo School of MedicineDivision of Clinical (LIM-07), Department of Gastroenterology, University of São Paulo School of MedicineDivision of Clinical (LIM-07), Department of Gastroenterology, University of São Paulo School of MedicineIntroduction: Non-Alcoholic Fatty Liver Disease (NAFLD) covers a wide spectrum of disease, ranging from simple steatosis to cirrhosis. Liver biopsy is still the gold standard for assessing fibrosis, but there is a need to seek non-invasive biomarkers that can also be efficient in predicting fibrosis. Objectives: To evaluate the role of microRNAs miR-21, miR-29a, miR-122, miR-155 and miR-181a in the phenotypic expression of NAFLD, correlating their serum levels with the different stages of the disease. Methods: Cross-sectional study carried out on 108 NAFLD patients diagnosed by liver biopsy. In the histological analysis, the degrees of fibrosis and NAFLD activity score (NAS) were obtained. The FIB-4 and NAFLD fibrosis score were calculated and compared with the degree of fibrosis by biopsy. The comparison between the distributions of microRNA values according to the presence or absence of clinically expressed fibrosis (F2-4) was performed. The serum expression of microRNAs was also compared with the NAS of the biopsy. A multivariate logistic regression analysis was performed to build a score for predicting fibrosis using FIB-4 and Ln (miR-181a) as independent variables. Results: Among the microRNAs studied, only miR-181a showed a statistical difference between patients with clinically expressed fibrosis and those without fibrosis (F0-F1) determined by liver biopsy (p = 0.017). FIB-4 revealed an AUC on the ROC curve of 0.667 to predict clinically expressed fibrosis (F2-F4). When assessed using the score in association with Ln (miR-181a), there was an improvement in the ROC curve, with AUC of 0.71. There was no correlation between the serum levels of microRNAs miR-21, miR-29a, miR-122, miR-155 and miR-181a with the degrees of inflammatory activity determined by NAS. Conclusion: miR-181a can be used as a non-invasive method of predicting fibrosis in NAFLD, and an association of biomarkers has the potential to increase the accuracy of each method alone.http://www.sciencedirect.com/science/article/pii/S1665268121001988 |
| spellingShingle | Rodrigo Vieira Costa Lima Fernanda de Mello Malta José Tadeu Stefano João Renato Pinho Flair José Carrilho Claudia Pinto Marques Souza de Oliveira O-12 MIR-181A AS A BIOMARKER OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE Annals of Hepatology |
| title | O-12 MIR-181A AS A BIOMARKER OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE |
| title_full | O-12 MIR-181A AS A BIOMARKER OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE |
| title_fullStr | O-12 MIR-181A AS A BIOMARKER OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE |
| title_full_unstemmed | O-12 MIR-181A AS A BIOMARKER OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE |
| title_short | O-12 MIR-181A AS A BIOMARKER OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE |
| title_sort | o 12 mir 181a as a biomarker of fibrosis in non alcoholic fatty liver disease |
| url | http://www.sciencedirect.com/science/article/pii/S1665268121001988 |
| work_keys_str_mv | AT rodrigovieiracostalima o12mir181aasabiomarkeroffibrosisinnonalcoholicfattyliverdisease AT fernandademellomalta o12mir181aasabiomarkeroffibrosisinnonalcoholicfattyliverdisease AT josetadeustefano o12mir181aasabiomarkeroffibrosisinnonalcoholicfattyliverdisease AT joaorenatopinho o12mir181aasabiomarkeroffibrosisinnonalcoholicfattyliverdisease AT flairjosecarrilho o12mir181aasabiomarkeroffibrosisinnonalcoholicfattyliverdisease AT claudiapintomarquessouzadeoliveira o12mir181aasabiomarkeroffibrosisinnonalcoholicfattyliverdisease |